Royal Bank Of Canada Increases Gilead Sciences (NASDAQ:GILD) Price Target to $100.00

Key Points

• Royal Bank of Canada raised Gilead Sciences' price target from $98.00 to $100.00, indicating a potential downside of 14.37% from the current stock price.
• Gilead Sciences has received multiple upgrades from analysts, with Needham & Company raising its rating to "buy" with a new price target of $133.00.
• The company reported a quarterly EPS of $2.01, exceeding analysts' expectations, and has set its fiscal year 2025 guidance at 7.950-8.250 EPS.

Gilead Sciences (NASDAQ:GILD - Get Free Report) had its target price hoisted by stock analysts at Royal Bank Of Canada from $98.00 to $100.00 in a research report issued to clients and investors on Wednesday,MarketScreener reports. The firm presently has a "sector perform" rating on the biopharmaceutical company's stock. Royal Bank Of Canada's price objective would indicate a potential downside of 14.37% from the stock's current price.

GILD has been the subject of several other research reports. Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target for the company in a research note on Friday, July 25th. UBS Group increased their price objective on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a report on Friday, August 8th. Weiss Ratings reaffirmed a "buy (b)" rating on shares of Gilead Sciences in a research report on Saturday, September 27th. JPMorgan Chase & Co. lifted their target price on Gilead Sciences from $135.00 to $145.00 and gave the stock an "overweight" rating in a research report on Tuesday, September 16th. Finally, Daiwa America raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, August 19th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $117.67.

Gilead Sciences Stock Up 2.8%

Shares of NASDAQ:GILD opened at $116.78 on Wednesday. The firm has a 50 day simple moving average of $114.41 and a 200 day simple moving average of $110.06. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. Gilead Sciences has a 52 week low of $84.17 and a 52 week high of $121.83. The company has a market cap of $144.90 billion, a PE ratio of 23.26, a price-to-earnings-growth ratio of 0.77 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business's revenue for the quarter was up 1.4% on a year-over-year basis. During the same period in the prior year, the business earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, research analysts expect that Gilead Sciences will post 7.95 earnings per share for the current year.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the transaction, the insider directly owned 114,168 shares of the company's stock, valued at approximately $13,532,333.04. This trade represents a 19.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $113.94, for a total value of $1,139,400.00. Following the completion of the sale, the chief executive officer owned 605,725 shares of the company's stock, valued at approximately $69,016,306.50. This trade represents a 1.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 82,000 shares of company stock worth $9,402,130 in the last ninety days. 0.27% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of GILD. Rothschild Investment LLC grew its position in shares of Gilead Sciences by 1.9% in the second quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company's stock valued at $503,000 after purchasing an additional 84 shares during the last quarter. Ignite Planners LLC increased its position in Gilead Sciences by 1.1% during the third quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company's stock worth $880,000 after acquiring an additional 86 shares during the period. Archer Investment Corp boosted its stake in shares of Gilead Sciences by 1.2% in the second quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company's stock valued at $807,000 after buying an additional 87 shares during the period. Binnacle Investments Inc grew its position in Gilead Sciences by 14.3% during the second quarter. Binnacle Investments Inc now owns 702 shares of the biopharmaceutical company's stock worth $78,000 after buying an additional 88 shares in the last quarter. Finally, EPG Wealth Management LLC increased its stake in Gilead Sciences by 2.0% during the 2nd quarter. EPG Wealth Management LLC now owns 4,627 shares of the biopharmaceutical company's stock worth $513,000 after acquiring an additional 89 shares during the period. Institutional investors own 83.67% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.